Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with
worse treatment outcomes for patients, including higher mortality, than for drug-sensitive …

Background Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new
antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro …

Background Delamanid is one of two recently approved drugs for the treatment of multidrug-
resistant tuberculosis. We aimed to evaluate the safety and efficacy of delamanid in the first …

Delamanid (Deltyba®), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB)
drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible …

Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is the leading cause of
death from an infectious disease globally. The widespread and ever-increasing resistance to …

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-
resistant TB requires lengthy treatments with toxic drugs that are less effective than their first …

New approaches to the treatment of multidrug-resistant and extensively drug-resistant
tuberculosis (TB) are badly needed. Not only is the success rate of current treatment …

Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

Background In October 2014, the World Health Organization (WHO) issued an interim policy
guidance on the use of delamanid in the treatment of patients with multidrug-resistant …